The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.
Identifieur interne : 008709 ( Ncbi/Merge ); précédent : 008708; suivant : 008710The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.
Auteurs : Jolien Robijns [Belgique] ; Sandrine Censabella [Belgique] ; Paul Bulens [Belgique] ; Annelies Maes [Belgique] ; Jeroen Mebis [Belgique]Source :
- Lasers in medical science [ 1435-604X ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Photothérapie de faible intensité.
- radiothérapie : Tumeurs du sein.
- étiologie : Lymphoedème, Radiodermite, Stomatite.
- Essais cliniques comme sujet, Femelle, Humains, Tumeurs du sein.
English descriptors
- KwdEn :
- MESH :
- adverse effects : Low-Level Light Therapy.
- complications : Breast Neoplasms.
- etiology : Lymphedema, Radiodermatitis, Stomatitis.
- radiotherapy : Breast Neoplasms.
- Clinical Trials as Topic, Female, Humans.
Abstract
Breast cancer is the most common cancer in women worldwide, with an incidence of 1.7 million in 2012. Breast cancer and its treatments can bring along serious side effects such as fatigue, skin toxicity, lymphedema, pain, nausea, etc. These can substantially affect the patients' quality of life. Therefore, supportive care for breast cancer patients is an essential mainstay in the treatment. Low-level light therapy (LLLT) also named photobiomodulation therapy (PBMT) has proven its efficiency in general medicine for already more than 40 years. It is a noninvasive treatment option used to stimulate wound healing and reduce inflammation, edema, and pain. LLLT is used in different medical settings ranging from dermatology, physiotherapy, and neurology to dentistry. Since the last twenty years, LLLT is becoming a new treatment modality in supportive care for breast cancer. For this review, all existing literature concerning the use of LLLT for breast cancer was used to provide evidence in the following domains: oral mucositis (OM), radiodermatitis (RD), lymphedema, chemotherapy-induced peripheral neuropathy (CIPN), and osteonecrosis of the jaw (ONJ). The findings of this review suggest that LLLT is a promising option for the management of breast cancer treatment-related side effects. However, it still remains important to define appropriate treatment and irradiation parameters for each condition in order to ensure the effectiveness of LLLT.
DOI: 10.1007/s10103-016-2056-y
PubMed: 27539464
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000662
- to stream PubMed, to step Curation: 000662
- to stream PubMed, to step Checkpoint: 000662
Links to Exploration step
pubmed:27539464Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.</title><author><name sortKey="Robijns, Jolien" sort="Robijns, Jolien" uniqKey="Robijns J" first="Jolien" last="Robijns">Jolien Robijns</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. jolien.robijns@uhasselt.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt</wicri:regionArea><wicri:noRegion>Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Censabella, Sandrine" sort="Censabella, Sandrine" uniqKey="Censabella S" first="Sandrine" last="Censabella">Sandrine Censabella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Bulens, Paul" sort="Bulens, Paul" uniqKey="Bulens P" first="Paul" last="Bulens">Paul Bulens</name><affiliation wicri:level="1"><nlm:affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Maes, Annelies" sort="Maes, Annelies" uniqKey="Maes A" first="Annelies" last="Maes">Annelies Maes</name><affiliation wicri:level="1"><nlm:affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Mebis, Jeroen" sort="Mebis, Jeroen" uniqKey="Mebis J" first="Jeroen" last="Mebis">Jeroen Mebis</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt</wicri:regionArea><wicri:noRegion>Hasselt</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27539464</idno><idno type="pmid">27539464</idno><idno type="doi">10.1007/s10103-016-2056-y</idno><idno type="wicri:Area/PubMed/Corpus">000662</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000662</idno><idno type="wicri:Area/PubMed/Curation">000662</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000662</idno><idno type="wicri:Area/PubMed/Checkpoint">000662</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000662</idno><idno type="wicri:Area/Ncbi/Merge">008709</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.</title><author><name sortKey="Robijns, Jolien" sort="Robijns, Jolien" uniqKey="Robijns J" first="Jolien" last="Robijns">Jolien Robijns</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. jolien.robijns@uhasselt.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt</wicri:regionArea><wicri:noRegion>Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Censabella, Sandrine" sort="Censabella, Sandrine" uniqKey="Censabella S" first="Sandrine" last="Censabella">Sandrine Censabella</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Bulens, Paul" sort="Bulens, Paul" uniqKey="Bulens P" first="Paul" last="Bulens">Paul Bulens</name><affiliation wicri:level="1"><nlm:affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Maes, Annelies" sort="Maes, Annelies" uniqKey="Maes A" first="Annelies" last="Maes">Annelies Maes</name><affiliation wicri:level="1"><nlm:affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt</wicri:regionArea><wicri:noRegion>3500 Hasselt</wicri:noRegion></affiliation></author><author><name sortKey="Mebis, Jeroen" sort="Mebis, Jeroen" uniqKey="Mebis J" first="Jeroen" last="Mebis">Jeroen Mebis</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt</wicri:regionArea><wicri:noRegion>Hasselt</wicri:noRegion></affiliation></author></analytic><series><title level="j">Lasers in medical science</title><idno type="eISSN">1435-604X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast Neoplasms (complications)</term><term>Breast Neoplasms (radiotherapy)</term><term>Clinical Trials as Topic</term><term>Female</term><term>Humans</term><term>Low-Level Light Therapy (adverse effects)</term><term>Lymphedema (etiology)</term><term>Radiodermatitis (etiology)</term><term>Stomatitis (etiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Lymphoedème (étiologie)</term><term>Photothérapie de faible intensité (effets indésirables)</term><term>Radiodermite (étiologie)</term><term>Stomatite (étiologie)</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (radiothérapie)</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Low-Level Light Therapy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Photothérapie de faible intensité</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term><term>Radiodermatitis</term><term>Stomatitis</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term><term>Radiodermite</term><term>Stomatite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Female</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Tumeurs du sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Breast cancer is the most common cancer in women worldwide, with an incidence of 1.7 million in 2012. Breast cancer and its treatments can bring along serious side effects such as fatigue, skin toxicity, lymphedema, pain, nausea, etc. These can substantially affect the patients' quality of life. Therefore, supportive care for breast cancer patients is an essential mainstay in the treatment. Low-level light therapy (LLLT) also named photobiomodulation therapy (PBMT) has proven its efficiency in general medicine for already more than 40 years. It is a noninvasive treatment option used to stimulate wound healing and reduce inflammation, edema, and pain. LLLT is used in different medical settings ranging from dermatology, physiotherapy, and neurology to dentistry. Since the last twenty years, LLLT is becoming a new treatment modality in supportive care for breast cancer. For this review, all existing literature concerning the use of LLLT for breast cancer was used to provide evidence in the following domains: oral mucositis (OM), radiodermatitis (RD), lymphedema, chemotherapy-induced peripheral neuropathy (CIPN), and osteonecrosis of the jaw (ONJ). The findings of this review suggest that LLLT is a promising option for the management of breast cancer treatment-related side effects. However, it still remains important to define appropriate treatment and irradiation parameters for each condition in order to ensure the effectiveness of LLLT.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27539464</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>19</Day></DateCreated><DateCompleted><Year>2017</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-604X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Lasers in medical science</Title><ISOAbbreviation>Lasers Med Sci</ISOAbbreviation></Journal><ArticleTitle>The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.</ArticleTitle><Pagination><MedlinePgn>229-242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10103-016-2056-y</ELocationID><Abstract><AbstractText>Breast cancer is the most common cancer in women worldwide, with an incidence of 1.7 million in 2012. Breast cancer and its treatments can bring along serious side effects such as fatigue, skin toxicity, lymphedema, pain, nausea, etc. These can substantially affect the patients' quality of life. Therefore, supportive care for breast cancer patients is an essential mainstay in the treatment. Low-level light therapy (LLLT) also named photobiomodulation therapy (PBMT) has proven its efficiency in general medicine for already more than 40 years. It is a noninvasive treatment option used to stimulate wound healing and reduce inflammation, edema, and pain. LLLT is used in different medical settings ranging from dermatology, physiotherapy, and neurology to dentistry. Since the last twenty years, LLLT is becoming a new treatment modality in supportive care for breast cancer. For this review, all existing literature concerning the use of LLLT for breast cancer was used to provide evidence in the following domains: oral mucositis (OM), radiodermatitis (RD), lymphedema, chemotherapy-induced peripheral neuropathy (CIPN), and osteonecrosis of the jaw (ONJ). The findings of this review suggest that LLLT is a promising option for the management of breast cancer treatment-related side effects. However, it still remains important to define appropriate treatment and irradiation parameters for each condition in order to ensure the effectiveness of LLLT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robijns</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6286-1581</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. jolien.robijns@uhasselt.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium. jolien.robijns@uhasselt.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Censabella</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulens</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebis</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Limburg Oncology Center, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lasers Med Sci</MedlineTA><NlmUniqueID>8611515</NlmUniqueID><ISSNLinking>0268-8921</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028022" MajorTopicYN="N">Low-Level Light Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011855" MajorTopicYN="N">Radiodermatitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013280" MajorTopicYN="N">Stomatitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Breast cancer</Keyword><Keyword MajorTopicYN="Y">Low-level light therapy</Keyword><Keyword MajorTopicYN="Y">Oncology</Keyword><Keyword MajorTopicYN="Y">Photobiomodulation therapy</Keyword><Keyword MajorTopicYN="Y">Supportive care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27539464</ArticleId><ArticleId IdType="doi">10.1007/s10103-016-2056-y</ArticleId><ArticleId IdType="pii">10.1007/s10103-016-2056-y</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Robijns, Jolien" sort="Robijns, Jolien" uniqKey="Robijns J" first="Jolien" last="Robijns">Jolien Robijns</name></noRegion><name sortKey="Bulens, Paul" sort="Bulens, Paul" uniqKey="Bulens P" first="Paul" last="Bulens">Paul Bulens</name><name sortKey="Censabella, Sandrine" sort="Censabella, Sandrine" uniqKey="Censabella S" first="Sandrine" last="Censabella">Sandrine Censabella</name><name sortKey="Maes, Annelies" sort="Maes, Annelies" uniqKey="Maes A" first="Annelies" last="Maes">Annelies Maes</name><name sortKey="Mebis, Jeroen" sort="Mebis, Jeroen" uniqKey="Mebis J" first="Jeroen" last="Mebis">Jeroen Mebis</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008709 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 008709 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27539464
|texte= The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27539464" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |